Iodine-123 is a cyclotron-produced radioisotope that emits gamma radiation at 159 keV—an energy window perfectly suited for high-resolution single-photon emission computed tomography (SPECT) imaging. At Protheragen, our radiochemistry team transforms this versatile isotope into precisely labeled molecular probes, empowering researchers and clinicians to visualize biological processes with exceptional clarity and minimal radiation burden.
Iodine-123 (I-123) occupies a distinctive position among diagnostic radionuclides due to its nearly ideal physical properties for nuclear medicine imaging. With a half-life of approximately 13.2 hours, it provides sufficient time for radiopharmaceutical preparation, quality control, and imaging procedures while limiting prolonged radiation exposure to patients and research subjects. The isotope decays exclusively by electron capture to tellurium-123, emitting monoenergetic gamma photons at 159 keV with an abundance of about 83%. This emission energy aligns optimally with the detection sensitivity of modern gamma cameras and SPECT systems, yielding images with superior spatial resolution and contrast compared to many other single-photon emitters. Production typically involves proton bombardment of enriched xenon-124 or tellurium-124 targets in a cyclotron, followed by chemical isolation and purification to obtain sodium iodide-123 of high specific activity.
Fig 1. Synthesis of PSMA-m-TBSB (19), PSMA-p-TBSB (20); [127I]PSMA-m-IB (21), and [127I]PSMA-p-IB (22). (Hasnowo, Lutfi A., et al., 2023)
Radiolabeling with I-123 encompasses a diverse array of chemical strategies tailored to the molecular scaffold of interest. Direct electrophilic iodination—often mediated by oxidizing agents such as chloramine-T or iodogen-coated reaction vessels—remains the cornerstone approach for incorporating iodine into aromatic rings of small molecules, peptides, and antibody fragments. For compounds lacking inherent iodination sites, indirect labeling via bifunctional conjugation agents enables stable attachment of the radionuclide through prosthetic groups. The choice of labeling methodology profoundly influences the in vivo stability, specific activity, and immunoreactivity of the final radiopharmaceutical. Rigorous quality control measures, including instant thin-layer chromatography (ITLC), radio-HPLC, and filter integrity testing, ensure that each batch meets stringent purity criteria before release for preclinical or clinical application.
The global radiopharmaceutical market has witnessed remarkable diversification in I-123-labeled compounds, extending far beyond traditional thyroid imaging into neurodegenerative disease diagnosis, cardiac sympathetic innervation assessment, and targeted oncology imaging. The following table summarizes key I-123 radiopharmaceuticals currently advancing through various stages of research and clinical translation:
| Radiopharmaceutical | Molecular Target / Application | Clinical / Research Stage | Key Imaging Modality |
|---|---|---|---|
| I-123 Sodium Iodide | Thyroid function & morphology assessment | Established clinical use | SPECT / SPECT-CT |
| I-123 MIBG (Metaiodobenzylguanidine) | Adrenergic nerve terminals; neuroendocrine tumors | Clinical standard for pheochromocytoma & neuroblastoma imaging | SPECT / SPECT-CT |
| I-123 Ioflupane (DaTSCAN) | Dopamine transporters in striatal neurons | Clinical use for Parkinsonian syndrome differentiation | SPECT |
| I-123 BMIPP | Myocardial fatty acid metabolism | Clinical & research use for ischemic heart disease | SPECT |
| I-123 mIBG (Cardiac) | Cardiac sympathetic innervation density | Clinical use for heart failure risk stratification | SPECT |
| I-123 Labeled Antibody Fragments | PSMA, tumor-associated antigens | Preclinical & early clinical development | SPECT / SPECT-CT |
| I-123 Labeled RGD Peptides | Integrin αvβ3 expression in angiogenesis | Preclinical research | SPECT |
| I-123 Labeled Amino Acid Analogues | Amino acid transport in brain tumors | Preclinical & clinical research | SPECT / SPECT-CT |
Protheragen delivers end-to-end I-123 radiolabeling solutions designed to accelerate radiopharmaceutical development from initial concept through preclinical validation and into IIT clinical studies. Our integrated CRDMO and CRO platform combines deep radiochemistry expertise with robust analytical capabilities and flexible manufacturing scales, ensuring that each I-123-labeled compound is produced with the purity, specific activity, and stability required for demanding in vivo imaging and biodistribution studies. Whether your project requires a custom small-molecule tracer, a radiolabeled peptide, or an antibody fragment conjugate, our team partners with you to optimize every parameter of the labeling process.
We design and execute direct electrophilic iodination strategies for small-molecule drug candidates, receptor ligands, and metabolic probes. Our chemists optimize reaction conditions—including oxidant selection, pH, temperature, and reaction time—to achieve high radiochemical yield while preserving the structural integrity and biological activity of the parent compound.
Our team specializes in site-specific radiolabeling of peptides, antibody fragments, and scaffold proteins using both direct iodination and indirect bifunctional chelation approaches. We carefully control chelator-to-protein ratios and purify conjugates to remove unreacted precursors, ensuring high specific activity and preserved binding affinity for in vivo targeting applications.
From initial proof-of-concept labeling to scalable process optimization, we develop robust, reproducible synthesis protocols tailored to your compound class. This includes reaction parameter screening, stability assessment under various formulation conditions, and establishment of in-process control checkpoints.
Every I-123-labeled product undergoes comprehensive analytical characterization, including radio-TLC, radio-HPLC, specific activity determination, and pH/osmolality testing. We provide detailed batch records and certificates of analysis to support your preclinical documentation and regulatory submissions.
Leveraging our in vivo imaging infrastructure and in vitro analytical platforms, we support biodistribution studies, metabolite profiling, and quantitative whole-body autoradiography to characterize the pharmacokinetic behavior and tissue distribution of your I-123-labeled compound.
We evaluate the stability of I-123-labeled compounds in various buffer systems and formulation matrices, conducting real-time and accelerated stability studies to establish appropriate storage conditions and shelf-life specifications for your radiopharmaceutical candidate.
Our I-123 radiolabeling workflow is structured to deliver high-quality, well-characterized radiopharmaceuticals within the time constraints imposed by the isotope's 13.2-hour half-life. Each stage is executed by experienced radiochemists in dedicated hot laboratories equipped with appropriate shielding, ventilation, and analytical instrumentation.
1. Project Consultation & Labeling Strategy Design
We begin with a detailed discussion of your target molecule, intended application, and desired specific activity. Our radiochemists evaluate the chemical structure to identify optimal iodination sites and select the most appropriate labeling methodology—direct electrophilic substitution, prosthetic group conjugation, or chelator-mediated attachment.
2. Precursor Synthesis & Characterization
For indirect labeling approaches, we synthesize and fully characterize the non-radioactive precursor, including chelator conjugation or prosthetic group attachment. The precursor undergoes rigorous purity verification by HPLC and mass spectrometry before advancing to the radiolabeling stage.
3. Radiolabeling Reaction & Optimization
The I-123 isotope is introduced under carefully controlled reaction parameters. Our team systematically optimizes pH, temperature, precursor concentration, and reaction duration to maximize radiochemical yield while minimizing side-product formation and radiolytic degradation.
4. Purification & Isolation
The crude reaction mixture is purified using chromatographic techniques such as solid-phase extraction, size-exclusion chromatography, or semi-preparative HPLC. This step removes free iodide, unreacted precursor, and chemical byproducts to isolate the target radiolabeled compound.
5. Quality Control & Batch Release
The purified product undergoes a full QC panel: radiochemical purity by ITLC and radio-HPLC, specific activity calculation, pH and osmolality measurement, endotoxin screening, and sterility verification where applicable. Only batches meeting all predefined acceptance criteria are released.
6. Formulation, Stability Assessment & Delivery
The final product is formulated in the appropriate buffer or vehicle for your intended application. We conduct stability monitoring under specified storage conditions and provide the radiopharmaceutical along with a comprehensive certificate of analysis and stability data package.
Ready to advance your radiopharmaceutical project with precision I-123 radiolabeling? Reach out to us today to discuss your specific requirements, explore customized synthesis strategies, and discover how Protheragen can accelerate your path from molecular concept to clinical imaging. Our team is standing by to provide detailed proposals, feasibility assessments, and scientific consultations tailored to your program's unique needs.
Reference